Robledo ÁFH, Velasco VMA

Idioma: Español
Referencias bibliográficas: 24
Paginas: 173-176
Archivo PDF: 63.05 Kb.

FRAGMENTO

El sistema inmune innato es la primera línea de defensa del organismo contra microorganismos patógenos. La interacción entre las células del sistema inmune innato y los patógenos involucra un limitado repertorio de receptores codificados en línea germinal llamados receptores de reconocimiento de patrones (PRRs por sus siglas en inglés). Dentro del grupo de los PRRs se incluyen a los receptores tipo Toll (TLRs), receptores tipo lectina C (CLRs), receptores tipo NOD (NLRs) y receptores tipo RIG (RLRs). Todos estos receptores reconocen secuencias específicas presentes en moléculas microbianas, que se conocen como patrones moleculares asociados a patógenos (PAMPs por sus siglas en inglés). Al ser ligandos de los PRRs, dichas secuencias juegan un papel importante en la activación de la respuesta inmune innata producida por microorganismos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.

2. Gay N, Gangloff M, Weber A. Toll-like receptors as molecular switches. Nat Rev Immunol 2006; 6: 693-8.

3. Rock F, Hardiman G, Timans J, Kastelein R, Bazan J. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95: 588-93.

4. Diebold S. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008; 60: 813-23.

5. Gazzinelli R, Denkers E. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006; 6: 895-906.

6. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007; 12: 80-7.

7. Gibson S, Lindh J, Riter T et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.

8. Harrison C, Miller R, Bernstein D. Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994; 38: 2059-64.

9. Sparling J, Checketts S, Chapman M. Imiquimod for plantar and periungual warts. Cutis 2001; 68: 397-9.

10. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.

11. Schulze H, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-47.

12. Schön M, Bong A, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.

13. Schön M, Wienrich B, Drewniok C et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122: 1266-76.

14. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003; 12: 109-25.

15. Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 2005; 44: 14-9.

16. Martinez-Piñeiro J. BCG vaccine in superficial bladder tumors: eight years later. Eur Urol 1984; 10: 93-100.

17. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6: 133-40.

18. Krieg A. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-84.

19. Cooper C, Davis H, Morris M et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24: 693-701.

20. Verthelyi D, Gursel M, Kenney R et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol 2003; 170: 4717-23.

21. Garay R, Viens P, Bauer J et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563: 1-17.

22. Sato K, Saiki I, Yoo Y et al. DT-5461, a new synthetic lipid A analogue, inhibits lung and liver metastasis of tumor in mice. Jpn J Cancer Res 1992; 83: 1081-7.

23. Nakatsuka M, Kumazawa Y, Homma J, Kiso M, Hasegawa A. Inhibition in mice of experimental metastasis of B16 melanoma by the synthetic lipid A-subunit analogue GLA-60. Int J Immunopharmacol 1991; 13: 11-9.

24. Ulevitch R. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004; 4: 512-20.